Genetic Testing for MEN1 and MEN2 Detection
For MEN1 detection, order germline MEN1 gene sequencing (including DNA sequence analysis, multiplex ligation-dependent probe amplification, or next-generation sequencing multigene panels), and for MEN2 detection, order germline RET proto-oncogene mutation analysis 1, 2.
MEN1 Genetic Testing Approach
Initial Testing
- Primary test: MEN1 gene germline mutation analysis using:
- DNA sequence analysis
- Multiplex ligation-dependent probe amplification (MLPA) to detect copy number variations
- Next-generation sequencing multigene/targeted panel testing 1
If Initial Testing is Negative
If you suspect MEN1 clinically (patient has ≥2 MEN1-associated tumors) but initial testing is negative, proceed algorithmically:
- Repeat testing using a different bioinformatic pipeline or library to overcome potential bias 1
- Consider whole-exome or whole-genome sequencing, which detects MEN1 mutations in approximately 50% of initially negative patients and can identify mosaic mutations 1
- Test for phenocopy genes based on clinical presentation:
- CDKN1B (MEN4)
- RET (MEN2)
- MAX (MEN5)
- CDC73, CASR, AIP 1
Important caveat: 10-30% of patients with clinical MEN1 remain mutation-negative despite comprehensive testing. These patients have a more favorable prognosis with less aggressive disease, median ages of tumor manifestation 13 and 9 years later for first and second tumors respectively, and 14 years greater median survival (87 vs 73 years) compared to MEN1 mutation-positive patients 1.
MEN2 Genetic Testing Approach
Primary Testing
- RET proto-oncogene germline mutation analysis 2, 3
- Focus on two functional domains:
- Extracellular ligand-binding domain (associated with MEN2A and familial MTC)
- Intracellular catalytic domain (associated with MEN2A, MEN2B, and familial MTC) 4
Clinical Context
- MEN2A: Medullary thyroid carcinoma (MTC), pheochromocytoma, primary hyperparathyroidism 3
- MEN2B: MTC, pheochromocytomas, mucosal neuromas, ganglioneuromas 3
Practical Multigene Panel Recommendations
Given the overlap and phenocopy potential, ASCO guidelines recommend including both MEN1 and RET in multigene panels for patients with:
- Medullary thyroid carcinoma: RET (strongly recommended) 2
- Adrenocortical tumors: MEN1 (among other genes) 2
- Pheochromocytomas/paragangliomas: RET, MAX (among other genes) 2
Critical pitfall: Approximately 10% of individuals in MEN1 families with clinical manifestations may be phenocopies—they have sporadic tumors but don't carry the familial mutation 1. Always confirm genetic status rather than assuming inheritance based on clinical presentation alone, as this substantially alters screening strategy.
Testing Indications
Order MEN1 testing for patients with:
- Family history of hyperparathyroidism
- Hyperparathyroidism plus one other MEN1-related tumor
- Hyperparathyroidism with multiglandular hyperplasia at young age (<30 years) 5
Order RET testing for patients with:
- Personal or family history of medullary thyroid carcinoma
- Pheochromocytoma with family history
- Clinical features of MEN2A or MEN2B 2, 3
Note: Because BRCA1, BRCA2, and Lynch syndrome genes are highly prevalent and important, it's reasonable to include these in any multigene panel for cancer patients undergoing germline testing, though they are not specific to MEN syndromes 2.